Colon cancer genetic testing is a method to guide the selection of targeted drugs, and genetic testing is subject to gene mutation and no gene mutation. Currently, the commonly used clinical testing genes mainly include RAS, BRAF, HER-2, microsatellite instability (MSI), etc., in order to clarify the molecular characteristics of the patient’s disease and to select the corresponding targeted drug therapy.
1. Cetuximab is recommended for wild-type RAS and BRAF with primary foci on the left side of the colon, and bevacizumab is recommended for primary foci on the right side of the colon, and bevacizumab can be considered as a targeted therapy for RAS or BRAF mutation.
2. Microsatellite instability (MSI) is mostly caused by MMR gene mutation and dysfunction, and PD-L1 inhibitor immunotherapy can be chosen for patients with MSI-H/dMMR.
3. HER-2 is an independent risk factor affecting patients’ prognosis, which is positively correlated with the depth of tumor infiltration, lymph node metastasis, and tumor stage, and trastuzumab-targeted therapy can be chosen for HER-2-positive patients.
In addition, patients can also choose regorafenib, furaquintinib and other drugs to treat colon cancer according to different indications of the drugs. Please strictly follow the doctor’s prescription for drug treatment, and do not use drugs on your own.